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Abstract The purpose of this study is to compare (Dutch)
Voice Handicap Index (VHIvumc) scores from a selected
group of patients with voice problems after treatment for
early glottic cancer with patients with benign voice disor-
ders and subjects from the normal population. The study
included a group of 35 patients with voice problems after
treatment for early glottic cancer and a group of 197 patients
with benign voice disorders. Furthermore, VHI scores were
collected from 123 subjects randomly chosen from the nor-
mal population. VHI reliability was high with high internal
consistency and test–retest stability. VHI scores of glottic
cancer patients were similar to those of patients with voice
problems due to benign lesions. Both groups of patients
were clearly deviant from the normal population. Within the
normal population, 16% appeared to have not-normal
voices. Based on ROC curves a cut-oV score of 15 points
was deWned to identify patients with voice problems in daily
life. A clinical relevant diVerence score of 10 points was
deWned to be used for individual patients and of 15 points to
be used in study designs with groups. Patients with voice
problems after treatment for early glottic cancer encounter
the same amount of problems in daily life as the other voice-
impaired patients. The VHI proved to be an adequate tool
for baseline and eVectiveness measurement of voice.
Keywords Voice handicap index · Quality of life · 
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Introduction
Voice impairment in patients after treatment for early glot-
tic cancer has been reported in several studies, ranging from
14 to 92% of the patients [1, 6, 9, 16, 24, 25]. Furthermore,
several studies on the inXuence of voice problems on qual-
ity of life revealed that in 27 up to 58% of the patients expe-
rienced diYculties in communication abilities leading to a
disrupted social life [3, 8, 12, 17, 19–22, 25]. To enable
quick screening on voice problems, a short 5-item voice-
screening questionnaire was developed and validated,
which proved to be feasible in clinical practice [22]. A
more detailed multidimensional voice analysis protocol is
however recommended for monitoring voice intervention
and for research purposes [24], including a structured ques-
tionnaire such as the Voice handicap index (VHI). The VHI
is a validated 30-item questionnaire measuring psychoso-
cial handicapping eVects of voice disorders [7] and is used
in several studies on patients after treatment for early glot-
tic cancer with mean VHI scores ranging from 12 to 34
points [3, 8, 12, 19]. Most of these studies include patients
with and without deviant voice quality and mean VHI data
are therefore not informative on the amount of problems
that patients with voice impairment after oncological treat-
ment encounter in daily life. In a study on 23 patients with
voice problems after oncological treatment, Van Gogh et al.
[23] reported a mean VHI score of 35. However,
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1034 Eur Arch Otorhinolaryngol (2007) 264:1033–1038interpretation of how cancer patients cope with voice prob-
lems compared to patients with voice problems due to
benign laryngeal lesions and compared with the normal
population is diYcult because of some underexposed psy-
chometric characteristics of the VHI: data from the normal
population are limited, no clear clinical cut-oV score is
available, and information on clinical relevant diVerence
scores is scarce.
The purpose of this study is to compare voice problems
of patients after treatment for early glottic cancer with
voice problems as reported by patients with benign voice
disorders and subjects from the normal population. The
study will also provide psychometric information of the
VHI regarding internal consistency, reliability, normative
data and a clinical cut-oV score, and clinical relevant diVer-




The patient sample consisted of 232 subjects: 35 patients
with voice problems after treatment for early glottic cancer
and 197 patients with voice problems due to benign voice
disorders.
Patients after treatment for early glottic cancer (carci-
noma in situ, T1 and T2 tumours) were selected based on a
validated voice-screening questionnaire; having a voice
problem was deWned as a score of 5 or higher (on a 10-point
scale) on one of the 5 voice items [22]. Of these 35 patients,
33 were males, 2 females; the median age was 62 years
(range: 41–81); mean post-oncological treatment time was
32 months (range: 6–135). Treatment included radiother-
apy (n = 24) or endoscopic laser surgery (n = 11); mean
VHI scores regarding treatment modality were comparable
(37 vs. 36 points).
Patients with voice problems due to benign voice disor-
ders were randomly selected from the patient population at
our voice clinic. This cohort of 197 patients included 44
patients with vocal fold paresis, 84 with structural lesions
(polyps, nodules, scarring, granuloma), 10 patients with
Reincke’s oedema, 55 patients with laryngitis, and 5
patients with laryngeal trauma. Of these 197 patients, 82
were males and 115 females; median age was 46 years
(range 18–90).
Controls
The group of 123 randomly selected controls from the nor-
mal population (employees from the hospital and (acquain-
tances of) relatives and neighbours of the researchers)
consisted of 54 males and 58 females (gender was not indi-
cated by 11 subjects); median age was 55 years (range 23–
87).
Voice handicap index
The VHI is a validated questionnaire measuring psychoso-
cial handicapping eVects of voice disorders and was trans-
lated and validated in Dutch. The VHI consists of 30
statements on voice-related aspects in daily life (with 5
response levels, scored 0 to 4). Summarising the scores on
the 30 statements leads to a total VHI score, ranging from 0
to 120. A higher score corresponds to a worse voice-related
functional status. Furthermore, the VHI includes an overall
question on the quality of the voice with four response lev-
els ranging from 0 (good), 1 (reasonable), 2 (moderate), 3
(poor). All VHI questionnaires were collected at baseline
(i.e. before logopedic, surgical or medical voice treatment).
To assess test–retest reliability, a subset of 30 patients (11
cancer, 13 structural lesion, 2 Reincke’s oedema, 2 laryngi-
tis, and 2 pareses) Wlled out the VHI twice, with a mean
interval period of 3.5 months (range 1–6 months) without
any voice intervention.
Statistical analyses
Because of the skewed distribution of the VHI scores of the
control group (the patient group showed normal distribu-
tion), independent Mann–Whitney tests (U test) and Krus-
kal–Wallis analysis-of-variance-by-ranks tests (H test)
were used with a two-sided probability level of ·0.05 to
compare subject groups and to assess the association of
VHI scores with age, gender, and self-reported voice qual-
ity.
The relations between VHI scores and case of voice
impairment was evaluated with Receiver Operating Char-
acteristics (ROC) analyses, using the area under the curve
(AUC) as a summary measure of the overall discriminative
ability of the VHI. In addition to ROC analyses, the sensi-
tivity and speciWcity were calculated at various cut-oV
scores.
Internal consistency of the VHI was assessed by Cron-
bach’s alpha. Test–retest stability was determined by
Spearman’s correlation coeYcient between the Wrst and
the second (repeated) ratings. The clinical relevant diVer-
ence score to be used in individual patients was deWned as
the maximum deterioration or improvement between test
and retest scores. The clinically relevant diVerence score to
be used in group study designs was deWned based on an
eVect size (ES) of 0.80, being deWned as the diVerence
between the experimental group mean minus the control
group mean divided by the standard deviation of the
control group.123
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Reliability
Internal consistency of the VHI proved to be good with
Cronbach’s alpha ranging from 0.87 (123 subjects from the
normal population), 0.90 (35 glottic cancer patients), to
0.92 (196 voice-impaired patients), and 0.96 for the total
group. Test–retest scores of the 30 patients who Wlled in the
VHI twice over a mean period of 3.5 months (range 1–
6 months) attested high test–retest stability with Spear-
man’s rho of 0.95 (P < 0.01).
Voice-impaired patients and the normal population
Within the normal population 16% subjects judged their
own voices as not good (score > 0 on the overall question
on the quality of the voice) versus 93% of the patients with
benign voice disorders and 94% of the cancer patients.
Voice handicap index scores of glottic cancer patients
were similar to those of patients with voice problems due to
benign lesions (P = 0.64), but clearly deviant from the nor-
mal population (P < 0.01) as were the scores of the total
group of patients with benign voice disorders (P < 0.01).
An overview is given in Fig. 1. Because of this similarity
between voice patient groups, further analyses were carried
out on the total group of voice-impaired patients (n = 232).
Sensitivity and speciWcity of the VHI in detecting voice-
impaired patients using a range of cut-oV points is shown in
Table 1. The AUC was 0.98 (95% CI: 0.97–0.99) indicat-
ing good overall discriminative ability of the VHI. Table 2
shows that sensitivity and speciWcity is good with a cut-oV
point between 13 and 17. A cut-oV point of 15 (or higher)
on the VHI scale is proposed to identify patients with voice
problems in daily life, because of a good degree of sensitiv-
ity and a sound (16% of the normal population judged their
own voices as not-good) degree of speciWcity.
Age, gender, and voice quality
No association between the VHI scores with gender was
found for the normal population (P = 0.86) or for the voice-
impaired patients (P = 0.59).
Regarding age, no clear associations were present either
in the normal population (r = 0.03, P = 0.97) or the voice-
impaired patients (r = 0. 01, P = 0.99).
Self-ratings of voice quality appeared to be clearly
related to VHI scores with Spearman’s rho ranging from
0.32 for the normal population to 0.48 for the voice-
impaired patients (P < 0.001).
DiVerence scores for individuals
The diVerence score between the Wrst and second rating
appeared not to be dependent (Spearman’s r = ¡0.005,
P = 0.98) on the height of the VHI score (Fig. 2). Individual
diVerence scores between the Wrst and second ratings
remained within ten points, ranging from ¡9 to +10 points.
Therefore a 10-point shift can be deWned as a clinical rele-
vant diVerence score to be used for single individual
patients.
Fig. 1 Boxplots presenting Voice handicap index scores for various
subjects groups: normal population, patients with vocal fold paresis,
larynx traumata, structural vocal fold lesions, Reincke’s oedema, lar-
yngitis, and patients with voice problems after treatment for early glot-
tic cancer
Table 1 Overview of various Voice handicap index cut-oV points
regarding sensitivity and speciWcity
In bold, the proposed cut-oV point of 15 points or lower, which com-
bines good Positive Predictive Value with high sensitivity and sound
speciWcity
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To deWne a relevant diVerence score for study designs with
groups, determination of the eVect size (ES) was used. ES
above 0.80 represents a large statistical and clinical diVer-
ence. From this study, standard deviations of the groups of
voice-impaired patients at baseline ranged from 10.60
(trauma), 15.98 (early glottic cancer), 18.43 (paresis), 19.78
(structural lesions), to 20.50 (oedema and laryngitis); the
standard deviation of the total group of voice-impaired
patients (n = 232) was 19.40. Table 2 represents an over-
view of eVect sizes regarding various diVerence scores with
a standard deviation of 19.40 as representative for the total
group of voice-impaired patients. The results show that a
diVerence score of 15 points or more is clinically relevant
in comparing groups of patients.
Discussion
The results of this study demonstrated a signiWcant diVer-
ence in mean VHI scores between patients with either
benign voice pathology or voice pathology following treat-
ment for glottic malignancy as compared to the normal
population, which is in concordance with various previous
studies. These studies, all about benign organic and/or
functional voice disorders reported mean VHI scores vary-
ing from 11 to 47 which were found to diVer signiWcantly
from controls with normal voices [4, 5, 11–13]. Nawka [11]
was the Wrst to report a signiWcant diVerence between 9
patients with voice problems due to a malignant tumour
(mean VHI score 34 points) and 16 normal control subjects
(mean VHI score 7 points); moreover they also did not Wnd
a diVerence in VHI score between various diagnosis groups
(benign organic or functional voice disorders (n = 159),
neurogenic voice disorders (n = 32) or malignant voice dis-
orders (n = 9)). From our results and the results as reported
by Nawka et al., it is clear that voice problems in daily life
of cancer patients are similar to those of patients with
benign voice impairment. One could Wnd this result remark-
able because it might be expected that patients being cured
of a malignancy experience the inherent voice impairment
in a less negative way than patients cured of a benignancy.
The secondary aim of this study was to assess some
underexposed psychometric characteristics of the VHI.
Internal consistency proved to be good, as was test–retest
stability. Regarding identiWcation of voice-impaired
patients, several authors used controls (subjects from the
normal population without voice problems) in their rando-
mised controlled studies on VHI change and reported mean
“normal” values varying from 2.3 to 10.5 points but neither
of them made a reliable eVort to deWne a cut-oV point [4, 5,
11, 12, 13]. The present study revealed a cut-oV point of 15
to identify patients with voice problems in daily life.
Regarding clinical relevant diVerence scores, we found a
diVerence score of 10 points to be useful for individuals in
clinical practice and 15 points to be useful in study group
designs. Jacobson et al. reported a shift of 18 points as a
valuable diVerence score to measure eYcacy of speciWc
voice treatment techniques, but no clear analysis descrip-
tion was given [7]. Another non-statistical approach to
deWne a clinically relevant diVerence score to be used in
group design studies is to line up published studies on the
eYcacy of voice treatment and assess diVerence score
appearing to be signiWcant or non-signiWcant. Four studies
Table 2 Overview of various Voice handicap index diVerence scores
regarding eVect size (with standard deviation of 19.40 as found in the
total group of voice-impaired patients)
In bold, the proposed clinical relevant diVerence score of 15 points or
more to be used in group-study designs










Fig. 2 Scatter plot showing the (absent) relation between the Wrst VHI
score and the diVerence score between the Wrst and second repeated
VHI score as reported by 30 patients (Spearman’s r = -0.005)123
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benign voice pathologies or voice pathologies following
treatment for glottic malignancy, showed signiWcant
improvement of the mean VHI with a range of 12 to 18
points [10, 14, 15, 23]. On the contrary, Speyer [18]
reported a non-signiWcant median improvement of 6 points
after voice therapy in patients with a diversity of chronic
benign voice disorders. Other studies on the eVect of sev-
eral medical treatment modalities for diVerent benign voice
disorders show a mean VHI improvement ranging from 13
to 46 points [2, 13, 26]. All these studies on the eYcacy of
voice intervention on various voice patient groups reveal
that a statistical diVerence score is at least 12 points. A
meta-analysis could provide further information but it
seems too early to perform such as study because of the
limited number of studies on eYcacy of voice treatment at
this moment. In the mean time, we propose a diVerence
score of 15 points signifying a statistical and clinical high
eVect size.
The proposed cut-oV point and the clinical diVerence
scores in this study are not meant to be conclusive, mainly
because of the Dutch origin of the data, which may have
inXuenced the results. Currently, a European VHI Study
Group is working on comparison of various translations of
the VHI to assess equivalence. The Wrst preliminary results
reveal that there are only minor diVerences between the
included versions, but further data exploring is ongoing.
Conclusion
Patients with voice problems after treatment for early glot-
tic cancer encounter the same amount of problems in daily
life as other voice-impaired patients and therefore require
the same attention and care for this sequel to their initial
cancer treatment. Furthermore, the VHI proved to be an
adequate tool for baseline and eVectiveness measurement
of voice.
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